Aceto (NASDAQ:ACET) and biOasis Technologies (OTCMKTS:BIOAF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.
Aceto pays an annual dividend of $0.04 per share and has a dividend yield of 1.8%. biOasis Technologies does not pay a dividend. Aceto pays out 100.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Aceto has raised its dividend for 2 consecutive years.
This table compares Aceto and biOasis Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Aceto and biOasis Technologies’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aceto||$711.36 million||0.09||-$316.12 million||$0.04||54.25|
|biOasis Technologies||$460,000.00||30.45||-$4.12 million||N/A||N/A|
biOasis Technologies has lower revenue, but higher earnings than Aceto.
Institutional and Insider Ownership
57.6% of Aceto shares are held by institutional investors. 4.1% of Aceto shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Aceto has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, biOasis Technologies has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
This is a breakdown of recent ratings for Aceto and biOasis Technologies, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aceto presently has a consensus target price of $2.00, indicating a potential downside of 7.83%. Given Aceto’s higher possible upside, analysts clearly believe Aceto is more favorable than biOasis Technologies.
Aceto beats biOasis Technologies on 10 of the 13 factors compared between the two stocks.
Aceto Corporation engages in the development, marketing, sale, and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals, and agricultural protection products. The company operates in three segments: Human Health, Pharmaceutical Ingredients, and Performance Chemicals. The Human Health segment supplies raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and biochemicals used in pharmaceutical and nutritional preparations. This segment is also involved in developing and marketing generic pharmaceutical products. It sells its generic prescription and over-the-counter pharmaceutical products to wholesalers, chain drug stores, distributors, and mass merchandisers. The Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates to various generic drug companies. The Performance Chemicals segment provides specialty chemicals for use in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, and fuels and lubricants, as well as for food, flavor, paper, and film industries; dye and pigment intermediates used in the color-producing industries; and organic intermediates used in the production of agrochemicals. Its raw materials are also used in electronic parts for photo tooling, circuit boards, and production of computer chips. This segment also offers agricultural protection products comprising herbicides, fungicides, and insecticides, which control weed growth and the spread of insects and microorganisms; and sprout inhibitors for potatoes. The company serves various companies in the industrial chemical, agricultural, and human health and pharmaceutical industries primarily in the United States, Europe, and Asia. Aceto Corporation was founded in 1947 and is headquartered in Port Washington, New York.
About biOasis Technologies
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. Bioasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to perform research on the delivery of therapeutic compounds across the blood-brain barrier; and a strategic collaboration with BIOAGILYTIX for the development and validation of bioanalytical methods to support the xB3 TM-001 program. It also has a strategic collaboration with WuXi Biologics (Hong Kong) Limited for the development and manufacturing of xB3-001 to treat cancer. The company was incorporated in 2006 and is headquartered in Guilford, Connecticut.
Receive News & Ratings for Aceto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aceto and related companies with MarketBeat.com's FREE daily email newsletter.